Gulf Pharmaceutical Industries

JULPHAR

AEG000201018

Pharmaceuticals

Market Closed - Abu Dhabi Securities Exchange Other stock markets 06:55:00 2024-05-01 am EDT			5-day change	1st Jan Change
0.964 ^AED	+2.44%		+1.47%	+25.36%

Mar. 21	Gulf Pharmaceutical Industries Shares to be Suspended Ahead of Annual General Meeting	MT
Mar. 15	Abu Dhabi's Gulf Pharmaceutical Industries Resumes Trading Following FY23 Results Publication	MT

Gulf Pharmaceutical Industries Announces the Resignation of Ragheb Alshakhshir as Chief Scientific Officer

March 01, 2022 at 07:12 am EST

Gulf Pharmaceutical Industries announced the resignation of Ragheb Alshakhshir as Chief Scientific Officer. Reason for resignation is Personal Reasons.

Latest news about Gulf Pharmaceutical Industries

Gulf Pharmaceutical Industries Shares to be Suspended Ahead of Annual General Meeting	Mar. 21	MT
Abu Dhabi's Gulf Pharmaceutical Industries Resumes Trading Following FY23 Results Publication	Mar. 15	MT
Gulf Pharmaceutical Industries' FY23 Attributable Loss Widens; Revenue Up	Mar. 15	MT
Gulf Pharmaceutical Industries to Halt Trading During Board Meeting	Mar. 11	MT
Gulf Pharmaceutical Industries P.S.C. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 12	CI
Gulf Pharmaceutical Industries P.S.C. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 10	CI
Gulf Pharmaceutical Industries P.S.C. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
Gulf Pharmaceutical Industries P.S.C. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11	CI
Gulf Pharmaceutical Industries P.S.C. Approves Board Appointments	23-04-14	CI
Gulf Pharmaceutical Industries P.S.C. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-19	CI
Gulf Pharmaceutical Industries P.S.C. Announces Chief Executive Officer Changes	23-02-15	CI
Gulf Pharmaceutical Industries P.S.C. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-08	CI
Gulf Pharmaceutical Industries P.S.C. Announces Resignation of Sanjay Deshmukh as Chief Operating Officer	22-10-11	CI
Gulf Pharmaceutical Industries P.S.C. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-11	CI
Cigalah Group completed the acquisition of 51% stake in Alpha Pharma L.L.C. from Gulf Pharmaceutical Industries P.S.C..	22-05-18	CI
Gulf Pharmaceutical Industries P.S.C. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-15	CI
Gulf Pharmaceutical Industries P.S.C. Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-18	CI
Gulf Pharmaceutical Industries Announces the Resignation of Ragheb Alshakhshir as Chief Scientific Officer	22-03-01	CI
Quantum Genomics Société Anonyme Signs an Exclusive License and Production Agreement with Gulf Pharmaceuticals Industries Julphar	21-12-06	CI
Quantum Genomics Société Anonyme announced that it expects to receive $2 million in funding from Gulf Pharmaceutical Industries P.S.C.	21-12-05	CI
Gulf Pharmaceutical Industries P.S.C. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-11	CI
GlobalOne Healthcare acquired Gulf Inject LLC from Gulf Pharmaceutical Industries P.S.C.	21-09-04	CI
Gulf Pharmaceutical Industries P.S.C. completed the acquisition of remaining 60% stake in Planet Pharmacies LLC from KAMCO Investment Company K.S.C.P. and others for AED 286 million	21-07-07	CI
Cigalah Group agreed to acquire 51% stake in Alpha Pharma L.L.C. from Gulf Pharmaceutical Industries P.S.C..	21-06-15	CI
Gulf Pharmaceutical Industries P.S.C. agreed to acquire a 60% stake in Planet Pharmacies LLC for AED 286 million.	21-06-09	CI

Chart Gulf Pharmaceutical Industries

Duration

Period

More charts

Gulf Pharmaceutical Industries PSC (Julphar) is a United Arab Emirates-based public shareholding company engaged in manufacturing and selling of medicines, drugs and other types of pharmaceutical and medical compounds, in addition to cosmetic compounds. The Company maintains a range of product portfolio, which target major therapeutic segments, including endocrinology, anti-infective, cardiovascular and gastroenterology, over-the-counter, nephrology, dermatology, respiratory, metabolic and burn and wound management. The Company operates through a network of more than 10 manufacturing plants, and a logistics network. The Company has approximately 800 products in various dosage forms, and more in the pipeline. The Companyâs subsidiaries include Mena Cool FZE, which is engaged in the transportation, and Julphar Pharmaceuticals PLC, which is engaged in Manufacturing of medicines, wrapping and packing materials.

Sector

Pharmaceuticals

Calendar

2024-05-07 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Gulf Pharmaceutical Industries

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

SELL

Number of Analysts

Last Close Price

0.941 AED

Average target price

0.72 AED

Spread / Average Target

-23.49%

Consensus

Annual profits - Rate of surprise

Company calendar

Sector Specialty & Advanced Pharmaceuticals

	1st Jan change	Capi.
GULF PHARMACEUTICAL INDUSTRIES	+25.36%	296M
KYOWA KIRIN CO. LTD.	+12.55%	9B
SK BIOPHARMACEUTICALS CO., LTD.	-12.75%	4.96B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+42.38%	4.47B
YUHAN CORPORATION	+5.23%	3.9B
INDIVIOR PLC	+19.41%	2.45B
BETTA PHARMACEUTICALS CO., LTD.	-19.05%	2.41B
CHANGCHUN BCHT BIOTECHNOLOGY CO.	-28.72%	2.23B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	+11.13%	2.02B
SUPERNUS PHARMACEUTICALS, INC.	+5.81%	1.65B

Specialty & Advanced Pharmaceuticals